Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Selective RET kinase inhibitor

Pralsetinib (Specialist drug)

Brand names: Gavreto

Pralsetinib is an oral selective RET kinase inhibitor used in RET-fusion-positive non-small-cell lung cancer and certain RET-altered thyroid cancers.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively inhibits RET kinase activity, including oncogenic RET fusions and mutations, blocking downstream proliferative signalling.

Prescribing in practice

  • Pneumonitis/interstitial lung disease can occur and may be serious, so new or worsening respiratory symptoms must prompt urgent assessment and treatment interruption.
  • Use requires a confirmed RET gene fusion or mutation by validated testing.
  • Hypertension, hepatotoxicity, haemorrhagic events, and cytopenias require monitoring and dose modification.

Monitoring

Monitor blood pressure, liver function, full blood count, and for pulmonary symptoms throughout treatment.

Counselling the patient

  • Report new or worsening cough, breathlessness, or fever promptly, as these may indicate a lung problem.
  • Attend blood-pressure and blood-test monitoring as arranged.
  • This medicine can harm an unborn baby; use effective contraception as advised.

Evidence & guidelines

The ARROW study supported approval of pralsetinib in RET-fusion-positive lung and thyroid cancers.

Reference: NICE TA812; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways